company background image
ABUS logo

Arbutus Biopharma NasdaqGS:ABUS Stock Report

Last Price

US$2.54

Market Cap

US$455.9m

7D

-6.6%

1Y

-15.9%

Updated

18 Mar, 2024

Data

Company Financials +

Arbutus Biopharma Corporation

NasdaqGS:ABUS Stock Report

Market Cap: US$455.9m

ABUS Stock Overview

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States.

ABUS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Arbutus Biopharma Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Arbutus Biopharma
Historical stock prices
Current Share PriceUS$2.54
52 Week HighUS$3.15
52 Week LowUS$1.69
Beta2.04
1 Month Change-12.41%
3 Month Change14.41%
1 Year Change-15.89%
3 Year Change-28.65%
5 Year Change-29.25%
Change since IPO-63.92%

Recent News & Updates

Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Feb 10
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 03
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Recent updates

Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Feb 10
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 03
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Nov 09
Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

Oct 24
Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Apr 26
We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

Nov 11
Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Oct 28
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'

Sep 12

Arbutus stock rises on US patent linked to hepatitis B therapy AB-729

Aug 30

Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Aug 06
Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial

Jul 20

Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release

Jun 29

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Jun 15
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

May 11
Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Mar 08
Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest

Mar 07

Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?

Dec 17

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Dec 14
Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment

Nov 20

Arbutus Biopharma: A First Assessment

Sep 15

We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Sep 11
We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment

Jun 29

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

May 21
Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Arbutus Bio slips 4% as Q1 revenue trails consensus

May 05

What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition

Mar 12
What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Feb 02
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years

Jan 07
Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years

Arbutus Biopharma (ABUS) Investor Presentation - Slideshow

Dec 17

What Is The Ownership Structure Like For Arbutus Biopharma Corporation (NASDAQ:ABUS)?

Dec 12
What Is The Ownership Structure Like For Arbutus Biopharma Corporation (NASDAQ:ABUS)?

Shareholder Returns

ABUSUS BiotechsUS Market
7D-6.6%-2.1%0.5%
1Y-15.9%9.7%29.0%

Return vs Industry: ABUS underperformed the US Biotechs industry which returned 10.4% over the past year.

Return vs Market: ABUS underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is ABUS's price volatile compared to industry and market?
ABUS volatility
ABUS Average Weekly Movement5.4%
Biotechs Industry Average Movement11.9%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: ABUS has not had significant price volatility in the past 3 months.

Volatility Over Time: ABUS's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a73Mike McElhaughhttps://www.arbutusbio.com

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.

Arbutus Biopharma Corporation Fundamentals Summary

How do Arbutus Biopharma's earnings and revenue compare to its market cap?
ABUS fundamental statistics
Market capUS$455.91m
Earnings (TTM)-US$72.85m
Revenue (TTM)US$18.14m

25.1x

P/S Ratio

-6.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABUS income statement (TTM)
RevenueUS$18.14m
Cost of RevenueUS$73.70m
Gross Profit-US$55.56m
Other ExpensesUS$17.29m
Earnings-US$72.85m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.41
Gross Margin-306.26%
Net Profit Margin-401.57%
Debt/Equity Ratio0%

How did ABUS perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.